The global bronchitis treatment market is projected to exhibit a significant growth, at a CAGR of around 3.4%, during the forecast period. The increasing number of smokers across the globe is increasing the prevalence of pulmonary disease. According to the World Health Organization (WHO), smoking is the one of the leading cause of mortalities across the globe, estimating to around seven million fatalities across the globe every year. Smoke caused by tobacco produces tar in the lungs, which ultimately results in coughs, wheezing, colds, lung cancer, and asthma. As per WHO, around 235 million people have asthma across the globe. High prevalence of asthma will result in investment toward the diseases by the government and patients for diagnosis and treatment of bronchitis.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/bronchitis-treatment-market
Furthermore, air pollution is also increasing globally which another major factor is leading to the growth of asthma patients. Significant rise in the level of air pollution is one of the major causes of lung diseases. As per WHO, around nine out of 10 people across the globe breathe polluted air and seven million mortalities occurred every year due to exposure to fine particles present in polluted air. The exposure to certain fine particles presents in air is the prime factor for air pollution that extremely affects lungs, leading to the development of bronchitis. According to WHO, over 90% of mortalities related to air pollution occurs in low and middle-income nations of the Asia and Africa. It has been followed by the Eastern-Mediterranean region, including the Latin America and Europe.
As per WHO, around 43% of all lung disease and lung cancer mortalities occur due to air pollution. It causes around 1.8 million mortalities annually. Around 25% of all mortalities attribute to air pollution, which estimated for around 2.4 million mortalities. Moreover, there are nearly 40% of global population, accounting for nearly 3 billion people who do not have access to clean cooking fuel and technologies at their homes. It is further considered as another main source of household air pollution. It represents that the rising air pollution concern is the major cause of lung diseases such as acute bronchitis, and asthma, which in turn is contributing to the growth of the bronchitis treatment market.
Nitrogen dioxide is considered as a deep lung irritant and is widely regulated by the US Environmental Protection Agency (EPA). The standard made by the EPA includes a minimal use of nitrogen oxide; not more than 188 micrograms/m3 for one-hour average or not more than 100 micrograms/m3 as an annual average. The burning of fossil fuels in industries, such as automobiles and power plants, leads to the formation of mixture of certain gases, which includes nitrogen dioxide and nitric oxide, and these are considered pollutants that affect the human health, including respiratory system. Therefore, there are several studies in place that have consistently found a significant prevalence of symptoms of chronic bronchitis in areas with higher level of air pollution. This, in turn, is leading to the growth of the global bronchitis treatment market.
Global Bronchitis treatment Market-Segmentation
By Technology
- Medication
- Antibiotics
- Anti-inflammatory drugs
- Bronchodilators
- Others (Mucolytics)
- Oxygen Therapy
A full report of Bronchitis Treatment Market is available at: https://www.omrglobal.com/industry-reports/bronchitis-treatment-market
Global Bronchitis treatment Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Abbott Laboratories
- Aurobindo Pharma Ltd.
- Bayer AG
- Boehringer Ingelheim International GmbH
- Cipla Ltd.
- Dr Reddy’s Laboratories Ltd.
- GlaxoSmithKline PLC
- Lupin Pharmaceuticals, Inc.
- Mayne Pharma Group Ltd.
- Merck & Co., Inc.
- Mucinex (Reckitt Benckiser Group plc)
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Teva Pharmaceutical Industries Ltd.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
